IAM
AMAM

Innovis Asset Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Innovis Asset Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$358K Buy
31,137
+14,311
+85% +$195K 0.14% 84
2023
Q2 		$277K Buy
+16,826
New +$212K 0.1% 125

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Innovis Asset Management's AMAM Position: Q3 2023 in Review

Innovis Asset Management increased its Ambrx Biopharma Inc (AMAM) stake by 85% in Q3 2023, buying an estimated $195K and bringing the position to 31,137 shares worth $358K. The position accounts for 0.14% of the portfolio, ranked #84.

Innovis Asset Management first reported a position in AMAM in Q2 2023 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold AMAM as of Q3 2023.

  • Innovis Asset Management held 31,137 shares of Ambrx Biopharma Inc worth $358K as of Q3 2023.
  • Innovis Asset Management bought 14,311 Ambrx Biopharma Inc shares in Q3 2023, an estimated $195K.
  • Ambrx Biopharma Inc made up 0.14% of Innovis Asset Management's portfolio in Q3 2023, its #84 holding.
  • Innovis Asset Management first reported a position in Ambrx Biopharma Inc in Q2 2023 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2023.

Based on Innovis Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.